[go: up one dir, main page]

NO975975L - Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav - Google Patents

Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav

Info

Publication number
NO975975L
NO975975L NO975975A NO975975A NO975975L NO 975975 L NO975975 L NO 975975L NO 975975 A NO975975 A NO 975975A NO 975975 A NO975975 A NO 975975A NO 975975 L NO975975 L NO 975975L
Authority
NO
Norway
Prior art keywords
preparation
receptor antagonists
vitronectin receptor
vitronectin
meanings
Prior art date
Application number
NO975975A
Other languages
English (en)
Other versions
NO975975D0 (no
Inventor
Volkmar Wehner
Hans Ulrich Stilz
Anuschirwan Peyman
Karlheinz Scheunemann
Jean-Marie Ruxer
Denis Carniato
Jean-Michel Lefrancois
Thomas Richard Gadek
Robert Mcdowell
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of NO975975D0 publication Critical patent/NO975975D0/no
Publication of NO975975L publication Critical patent/NO975975L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet forbindelser med formel I, A-B-D-E-F-G (D hvor A, B, D, E, F og G har de i patentkravene angitte betydninger, fremstilling og anvendelse derav som legemiddel. Forbindelsene anvendes også som vitronektinreseptor-antagonister og som inhibitorer av benresorpsjon.
NO975975A 1996-12-20 1997-12-19 Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav NO975975L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653645A DE19653645A1 (de) 1996-12-20 1996-12-20 Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung

Publications (2)

Publication Number Publication Date
NO975975D0 NO975975D0 (no) 1997-12-19
NO975975L true NO975975L (no) 1998-06-22

Family

ID=7815760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975975A NO975975L (no) 1996-12-20 1997-12-19 Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav

Country Status (19)

Country Link
US (1) US5990145A (no)
EP (1) EP0854145A3 (no)
JP (1) JPH10182617A (no)
KR (1) KR19980064419A (no)
CN (1) CN1200373A (no)
AR (1) AR010369A1 (no)
AU (1) AU729760B2 (no)
BR (1) BR9706386A (no)
CA (1) CA2225267A1 (no)
CZ (1) CZ411297A3 (no)
DE (1) DE19653645A1 (no)
HU (1) HUP9702509A3 (no)
ID (1) ID19245A (no)
IL (1) IL122643A0 (no)
NO (1) NO975975L (no)
NZ (1) NZ329429A (no)
PL (1) PL323968A1 (no)
TR (1) TR199701645A3 (no)
ZA (1) ZA9711315B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
US6545032B1 (en) 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
EP1371646B1 (en) * 2001-03-19 2010-05-19 Dainippon Sumitomo Pharma Co., Ltd. Aryl-substituted alicyclic compound and medical composition comprising the same
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
PL370176A1 (en) 2001-11-13 2005-05-16 3-Dimensional Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
EP1945262A2 (en) * 2005-10-20 2008-07-23 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
AR056155A1 (es) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
ES2472450T3 (es) 2007-01-18 2014-07-01 Merck Patent Gmbh Ligandos de integrinas para su uso en el tratamiento del cáncer de colon
CA2680275C (en) 2007-03-09 2016-08-23 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112360A1 (en) * 1991-06-28 1993-12-23 William Edward Bondinell Bicyclic fibrinogen antagonists
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08504194A (ja) * 1992-12-01 1996-05-07 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
CA2152631A1 (en) * 1992-12-21 1994-07-07 William Edward Bondinell Bicyclic fibrinogen antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
ES2186720T3 (es) * 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
ES2197950T3 (es) * 1995-06-29 2004-01-16 Smithkline Beecham Corporation Antagonistas del receptor de la integrina.
CN1209063A (zh) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
BR9612378A (pt) * 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
CA2241633A1 (en) * 1995-12-29 1997-07-10 William Henry Miller Vitronectin receptor antagonists
ATE212990T1 (de) * 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

Also Published As

Publication number Publication date
JPH10182617A (ja) 1998-07-07
EP0854145A2 (de) 1998-07-22
AU729760B2 (en) 2001-02-08
NZ329429A (en) 1999-05-28
HUP9702509A3 (en) 2001-04-28
ID19245A (id) 1998-06-28
AU4846497A (en) 1998-06-25
BR9706386A (pt) 2003-04-22
KR19980064419A (ko) 1998-10-07
DE19653645A1 (de) 1998-06-25
CZ411297A3 (cs) 1998-07-15
CN1200373A (zh) 1998-12-02
US5990145A (en) 1999-11-23
HU9702509D0 (en) 1998-03-02
CA2225267A1 (en) 1998-06-20
IL122643A0 (en) 1998-08-16
HUP9702509A2 (hu) 1999-06-28
PL323968A1 (en) 1998-06-22
TR199701645A2 (xx) 1998-07-21
AR010369A1 (es) 2000-06-07
TR199701645A3 (tr) 1998-07-21
NO975975D0 (no) 1997-12-19
MX9710389A (es) 1998-08-30
EP0854145A3 (de) 2000-03-22
ZA9711315B (en) 1998-06-22

Similar Documents

Publication Publication Date Title
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
NO983002L (no) Vitronectin-reseptor-antagonister
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
NO992821L (no) Ketobenzamider som calpain-inhibitorer
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
NO20001514L (no) Vitronectin-reseptor-antagonist
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
NO990662L (no) Trombin-inhibitorer
FR2684289B1 (fr) Implant intra-cortical, notamment pour la fixation de ligament.
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
TR200100885T2 (tr) 2-Metil-tieno-benzodiazepin formülasyonu
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
BR9813214A (pt) Antagonista de receptor vitronectina
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
BR0013749A (pt) Antagonistas dos receptores de vitronectina
WO2000007544A3 (en) Vitronectin receptor antagonists
NO20000518L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
NO944722L (no) 3-(fenylalkylaminoalkyloksy)-5-fenylpyrazol-forbindelser samt fremgangsmåter og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application